Fear of nausea a significant issue and often not discussed with
CALIFON, NJ, April 25 /CNW/ - PediatRx, Inc. (OTCBB: PEDX) today
commented on studies which reveal that chemotherapy-induced nausea and
vomiting is one of the most feared of all chemotherapy-related side
effects.1-9 The fear of nausea and subsequent vomiting is many times so significant
that patients can develop a condition known as 'anticipatory' nausea,
where the patient becomes nauseous primarily as a result of the fear of
becoming nauseous.9 This fear may be left unmentioned during discussions between patients
and healthcare professionals.
Certain medicines, called anti-emetics, can be used to prevent and treat
nausea and vomiting associated with chemotherapy and radiotherapy. A
class of anti-emetics, called 5HT3 receptor antagonists (or 5HT3s), are
often used for prevention and treatment of nausea and vomiting
associated with cancer therapy.
PediatRx, a hospital specialty company with a focus on oncology
supportive care, has recently commented on these findings.
"These studies highlight the important fact that patients undergoing
treatment for cancer can sometimes be more concerned about the consequences of the treatment rather than the treatment itself. The evidence also
points to this being a topic that often goes un-discussed between
healthcare practitioners and patients. For patients undergoing chemo-
or radio-therapy who may be unsuitable for other modes of
administration of the 5HT3, granisetron, or who prefer an oral liquid
anti-emetic, GRANISOL™, the only FDA-approved oral solution containing
granisetron, may offer an alternative," said Dr. Cameron Durrant, the
founder of PediatRx.
"One of the biggest differences between GRANISOL and other 5HT3s, is
that two teaspoonfuls of GRANISOL administered once per day controls
nausea and vomiting for 24 hours. Typically, other 5HT3s require
multiple doses throughout the day or an IV line. Additionally, GRANISOL
comes in a pleasant orange-flavored liquid," he added.
PediatRx offers a co-pay assistance program to help non-Medicaid or
Medicare patients pay for GRANISOL. This program, "GRANI Cares,"
provides up to $200 off the co-pay each time it is used, has no income
ceiling, and has no limit on the number of prescriptions that qualify.
"We are acutely aware of the cost pressures on healthcare providers,
payers and patients. That is why we developed this program to support
patients taking GRANISOL, which is the least restrictive co-pay
assistance program in its class," said Dr. Durrant.
For our co-pay program, visit GRANI Cares: http://www.121hm.com/offers/granisol
For disclaimer information, visit: http://www.121hm.com/offers/granisol/tandc.html
Patients and health care providers can contact their state Medicaid
program to find out if GRANISOL has been added at the current time. See
GRANISOL is indicated for the prevention of:
Nausea and vomiting associated with initial and repeat courses of
emetogenic cancer therapy, including high-dose cisplatin.
Nausea and vomiting associated with radiation, including total body
irradiation and fractionated abdominal radiation.
For full prescribing information, visit: http://www.pediatrx.com/products/pdf/granisol_pi.pdf
Selected Safety Information
GRANISOL is contraindicated in patients with known hypersensitivity to
the drug or any of its components.
QT prolongation has been reported with granisetron. Therefore, GRANISOL
Oral Solution should be used in caution with patients with pre-existing
arrhythmias or cardiac conduction disorders, as this might lead to
clinical consequences. Patients with cardiac disease, on cardio-toxic
chemotherapy, with concomitant electrolyte abnormalities and/or on
concomitant medications that prolong the QT interval are particularly
Safety and effectiveness in pediatric patients have not been
The most common side effects observed with administration of granisetron
were headache, asthenia, constipation, diarrhea, dyspepsia, and
Akechi T, Okuyama T, Endo C, et al. Cancer Sci. Anticipatory nausea among ambulatory cancer patients undergoing
chemotherapy: prevalence, associated factors, and impact on quality of
Akin S, Can G, Aydiner A, Ozdilli K, Durna Z. Quality of life, symptom
experience and distress of lung cancer patients undergoing
chemotherapy. Eur J Oncol Nurs. 2010;14(5):400-9.
Browall M, Persson LO, Ahlberg K, Karlsson P, Danielson E. Daily assessment of stressful events and coping among post-menopausal
women with breast cancer treated with adjuvant chemotherapy. Eur J Cancer Care. 2009;18(5):507-16.
Cohen L, de Moor CA, Eisenberg P, Ming EE, and Hu H.
Chemotherapy-induced nausea and vomiting: Incidence and impact on
patient quality of life at community oncology settings. Supportive Care in Cancer. 2007;15(5):497-503.
Dubey S, Brown RL, Esmond SL, et al. Patient preferences in choosing
chemotherapy regimens for advanced non-small cell lung cancer. Supportive Oncology. 2005;3(2)148-154.
Grunberg SM, Deuson RR, Mavros P, et al. Incidence of
chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261-2268.
Hawkins R and Grunberg S. Chemotherapy‐induced nausea and vomiting:
challenges and opportunities for improved patient outcomes. Clinical Journal of Oncology Nursing. 2009;13(1): 54-64.8.
Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed
chemotherapy-induced nausea and vomiting on patients, health resource
utilization and costs in German cancer centers. Annals of Oncology. 2004;15(3):526-536
Kris MG, Urba SG, Schwartzberg LS. Clinical roundtable monograph.
Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC
2010 discussion. Clin Adv Hematol Oncol. 2011;9(1):suppl 1-15.
For further information related to material contained in this release,
please contact Holmes World Media Inc., +1 512 981 7369
About PediatRx, Inc.
PediatRx, Inc. (www.pediatrx.com) is a hospital specialty pharmaceutical company which focuses on
treatments for patients suffering from serious conditions requiring
hospitalization. PediatRx trades on the OTCBB under the ticker symbol
PD 50 04/11
SOURCE PediatRx Inc.
For further information:
Research & Business Development
+1 908 975 0753